Thomas Shrader
Stock Analyst at BTIG
(3.31)
# 942
Out of 5,157 analysts
83
Total ratings
43.42%
Success rate
5.29%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALEC Alector | Upgrades: Buy | $6 | $2.38 | +152.10% | 5 | Mar 10, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $7 → $12 | $4.85 | +147.42% | 3 | Mar 2, 2026 | |
| DNLI Denali Therapeutics | Maintains: Buy | $32 → $36 | $21.43 | +67.99% | 5 | Mar 2, 2026 | |
| IVVD Invivyd | Reiterates: Buy | $10 | $1.83 | +446.45% | 3 | Feb 26, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $85 → $89 | $58.24 | +52.82% | 7 | Feb 26, 2026 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $1.81 | +1,281.22% | 3 | Feb 18, 2026 | |
| DRUG Bright Minds Biosciences | Maintains: Buy | $147 | $79.63 | +84.60% | 4 | Feb 17, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $27 → $28 | $20.88 | +34.10% | 2 | Feb 17, 2026 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $4 → $7 | $3.36 | +108.33% | 3 | Jan 27, 2026 | |
| NVAX Novavax | Reiterates: Buy | $19 | $10.69 | +77.74% | 1 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $10.27 | +55.79% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $4.90 | +226.53% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $5.01 | +79.64% | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $39 | $38.35 | +1.69% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.04 | +163.16% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $7.62 | +201.84% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $2.83 | +218.02% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $7.44 | +88.17% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $36.08 | +74.61% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.28 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.13 | +87.79% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $21.69 | +822.08% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $5.35 | +1,021.50% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $6.08 | +15.13% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.17 | +7,453.75% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.39 | +3,569.06% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.69 | +241.15% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.00 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.63 | +84.05% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $188.41 | +83.64% | 3 | Feb 21, 2019 |
Alector
Mar 10, 2026
Upgrades: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
Opus Genetics
Mar 2, 2026
Maintains: Buy
Price Target: $7 → $12
Current: $4.85
Upside: +147.42%
Denali Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $32 → $36
Current: $21.43
Upside: +67.99%
Invivyd
Feb 26, 2026
Reiterates: Buy
Price Target: $10
Current: $1.83
Upside: +446.45%
Vaxcyte
Feb 26, 2026
Maintains: Buy
Price Target: $85 → $89
Current: $58.24
Upside: +52.82%
NRx Pharmaceuticals
Feb 18, 2026
Reiterates: Buy
Price Target: $25
Current: $1.81
Upside: +1,281.22%
Bright Minds Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $147
Current: $79.63
Upside: +84.60%
Alto Neuroscience
Feb 17, 2026
Maintains: Buy
Price Target: $27 → $28
Current: $20.88
Upside: +34.10%
Acumen Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $4 → $7
Current: $3.36
Upside: +108.33%
Novavax
Jan 20, 2026
Reiterates: Buy
Price Target: $19
Current: $10.69
Upside: +77.74%
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $10.27
Upside: +55.79%
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $4.90
Upside: +226.53%
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $5.01
Upside: +79.64%
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $38.35
Upside: +1.69%
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $3.04
Upside: +163.16%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $7.62
Upside: +201.84%
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $2.83
Upside: +218.02%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $7.44
Upside: +88.17%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $36.08
Upside: +74.61%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $2.13
Upside: +87.79%
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $21.69
Upside: +822.08%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.35
Upside: +1,021.50%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $6.08
Upside: +15.13%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.17
Upside: +7,453.75%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.39
Upside: +3,569.06%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $4.69
Upside: +241.15%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.00
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.63
Upside: +84.05%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $188.41
Upside: +83.64%